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Abstract: Non-viral vectors have emerged as a promising alternative to viral gene delivery systems
due to their safer profile. Among non-viral vectors, recently, niosomes have shown favorable
properties for gene delivery, including low toxicity, high stability, and easy production. The three
main components of niosome formulations include a cationic lipid that is responsible for the
electrostatic interactions with the negatively charged genetic material, a non-ionic surfactant that
enhances the long-term stability of the niosome, and a helper component that can be added to improve
its physicochemical properties and biological performance. This review is aimed at providing recent
information about niosome-based non-viral vectors for gene delivery purposes. Specially, we will
discuss the composition, preparation methods, physicochemical properties, and biological evaluation
of niosomes and corresponding nioplexes that result from the addition of the genetic material onto
their cationic surface. Next, we will focus on the in situ application of such niosomes to deliver
the genetic material into immune-privileged tissues such as the brain cortex and the retina. Finally,
as future perspectives, non-invasive administration routes and different targeting strategies will
be discussed.
Keywords: gene delivery; non-viral vectors; niosomes; brain; retina
1. Introduction
It has been a long journey, with promising expectations and serious setbacks since gene therapy
was referred as a potential strategy to face monogenetic disorders 45 years ago, until nowadays, where
this advanced therapy is considered a realistic, although still uncommon, medical option for the
Pharmaceutics 2020, 12, 198; doi:10.3390/pharmaceutics12030198 www.mdpi.com/journal/pharmaceutics
Pharmaceutics 2020, 12, 198 2 of 29
treatment of both inherited and acquired human diseases [1]. The knowledge gained on the molecular
basis of genetic diseases along with recent advances in different research areas, such as biotechnology
or nanomedicine, have contributed to increasing the number of clinical trials based on gene therapy up
to around 2000 (http://www.abedia.com/wiley/). Such interest has accelerated the research investment
of many companies involved in the development of gene therapy-based drugs, and consequently, it is
expected that the therapeutic armamentarium will soon increase [2].
The main concept of gene therapy is quite simple and basically relies on the incorporation
of enough exogenous genetic material into a specific target cell in a safe way to modulate protein
expression related to the development of diseases that cannot be faced with conventional treatments [3].
More specifically, therapeutic genetic material can be supplied to cells with genetically modified viruses
(virotherapy) due to their natural ability to infect cells [4]. This approach is particularly interesting
to selectively infect and kill cancer cells, although the use of biological agents such as infecting
viruses for medical applications raises relevant safety concerns [5]. Another alternative to enhance
the expression of a specific protein whose low levels accelerate the development of certain diseases is
through the administration of bacterial plasmid DNA (pDNA) [6]. This strategy is normally applied
for the treatment of genetic diseases that follow an autosomic recessive inheritance pattern. However,
the main drawbacks of plasmid administration include the immune response generated against the
bacterial elements [7] and, in some cases, the big size of the plasmid that decreases transfection
efficiency process [8]. To minimize such disadvantages, unmethylated cytosine-phosphate-guanine
(CpG) dinucleotides from bacterial origin and other not relevant sequences related to the origin of
replication and the resistance to antibiotics have been removed from conventional plasmids resulting in
minicircle DNAs (mcDNAs), which reduce immunogenic response and enhance transfection efficiency,
allowing a sustained expression of the therapeutic gene (transgene) [9]. Other different approach
include the administration of exogenous genetic material in the form of small interfering RNA (siRNA),
or aptamers to inhibit protein expression by different mechanisms at a post-transcriptional level, or
the synthesis of antisense oligonucleotides (ASOs) that can regulate the expression of both precursor
RNA (pre-RNA) or mature RNA in the nucleus or cytosol, respectively [10–13]. These therapeutic
oligonucleotides are very sensitive to enzymatic degradation, and therefore, the biomacromolecules
must be stabilized with chemical modifications on their structure [11,14].
Normally, and in clear contrast to conventional drug-based therapies, marketed gene therapy
products are designed to get long-lasting therapeutic benefits and focus their interest on rare and
specific disorders that affect a reduced number of patients. In this sense, it is worth mentioning the
case of the recently approved Milasen® drug, which has been specifically designed for a single patient
suffering from Batten disease [13]. The unusual characteristics of gene therapy-based drugs also raise
ethical and social concerns related to the cost of such innovative treatments [2]. Some in vivo gene
therapy products currently approved for human use are summarized in Table 1.
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Table 1. Gene therapy-based drugs on market for in vivo human use, including synthetic oligonucleotides.
Year (Agency) Name Indication Genetic Material Administration Delivery System
2003
(FDA, China) Gendicine
Head and neck
squamous
cell carcinoma
Bacterial
plasmid
Intratumoral
injection Adenovirus
2004
(FDA, USA) Macugen
Age-related
macular
degeneration
Synthetic
aptamer
Intravitreal
Injection -
2005
(FDA, China) Oncorine
Nasopharyngeal
cancer
Viral
DNA
Intratumoral
injection Adenovirus
2010
(FDA, USA) Rexin-G
Meteastatic
pancreatic
cancer
Viral
RNA
Intravenous
infusion Retrovirus
2012 (Russian
ministry of
Healthcare)
Neovasculgen
Atherosclerotic
peripheral
arterial disease
Bacterial
plasmid
Intramuscular
injection -
2013
(FDA, USA)
Kynamro
(Mipomersen)
Homozygous
familial
hypercholesterolemia
Synthetic
ASO
Subcutaneous
injection -
2016
(FDA, EMA) Imylgic
Multiple solid
tumors
Viral
DNA
Intratumoral
injection
Oncolytic
Herpex simple
Virus
2016
(FDA, EMA)
Exondys 51
(Eteplirsen)
Duchene muscular
dystrophy
Synthetic
ASO
Intravenous
infusion -
2016
(FDA, EMA)
Spinraza
(Nusinersen)
Spinal muscular
atrophy
Synthetic
ASO
Intrathecal
administration -
2016
(FDA, EMA) Defibrotide
Veno-occlusive
disease
of liver
Single-stranded
oligodeoxyribo
nucleotides
Intravenous
infusion -
2018
(FDA, EMA)
Patisiran
(Onpattro)
Familial amyloid
polyneuropathy
RNA
interference
Intravenous
perfusion
Lipid
nanoparticle
2018
(FDA, EMA) Luxturna
Leber congenital
amaurosis
type 2
RPE 65
plasmid
Subretinal
injection
Adeno-associated
Virus
2018
(FDA)
Tegsedi
(Inotersen)
Transthyretin-mediated
amyloidosis
Synthetic
ASO
Subcutaneous
injection -
2019
(FDA)
Givlaari
(Givosiran)
Acute hepatic
porphiria
RNA
interference
Subcutaneous
injection -
2019
(EMA)
Waylivra
(Volanesorsen)
Familial
chylomicronemia
syndrome (FCS)
Synthetic
ASO
Subcutaneous
injection -
2019
(FDA)
Vyondys 53
(Golodirsen)
Duchene muscular
dystrophy
Synthetic
ASO
Intravenous
injection -
2019
(FDA) Zolgensma
Spinal muscular
atrophy
Bacterial
plasmid
Intravenous
infusion
Adeno-associated
Virus
Another emerging strategy to deliver transgenes into the organism is through the extraction
of cells from the patient, which after ex vivo genetic manipulation are implanted again into the
organism [15,16]. In fact, recently, many ex vivo gene therapy products such as Zalmoxis, Zyntelgo,
Invossa, Yeskarta, Kymriah and Strimvelis have been commercialized [17]. Such approaches use
both retro and lentivirus vectors to transduce allogenic and autologous cells for the treatment of
hematopoietic malignancies, osteoarthritis, or severe combined immunodeficiency diseases.
In addition to the previously described gene therapy approaches based on both gene
supplementation and gene suppression strategies, recent advances on genome editing tools by
CRISPR/Cas technology allow the correction of a specific mutation at a genomic level [18]. Due to
the huge treatment possibilities of such revolutionary genome editing tools, the number of scientific
publications in this area has considerably increased since 2014, and many clinical trials are underway,
especially in cancer and pathological disorders of the blood and eye [19]. In any case, although highly
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promising, still some concerns mainly related to the delivery strategy, the possibility of permanent
off target effects, or the efficiency to repair the mutation in a controlled manner need to be resolved
before reaching the market [20]. In this sense, the new modified version of the CRISPR/Cas systems
referred as “prime editing” holds great potential to promote the translation of this technology into
clinical practice [21].
Although few gene therapy products are available for human use, there is no doubt that this
market has significantly increased in the last few years. Consequently, it is reasonably estimated
that some products that nowadays are under clinical trials evaluation will soon reach the clinical
practice, which justify the optimism and financial investment of many biotechnology firms [1]. In
any case, more research efforts need to be focused on the development of safe and efficient genetic
material delivery systems to overcome the biological barriers that hamper the clinical application of
gene therapy. This issue is particularly relevant for the treatment of diseases that affect to sensitive and
immunologically isolated organs, such as brain and eye, where gene therapy-based drugs should be
preferably administered by non-invasive administration routes.
2. Biological Barriers
To be active at the place of action, gene delivery systems need to overcome both extracellular and
intracellular barriers for in vivo applications, while for ex vivo purposes, only intracellular barriers
can hamper their final performance [22]. Extracellular biological barriers to overcome will depend
mainly on the administration route, while intracellular barriers will differ according to the target cell.
2.1. Extracellular Barriers
From a practical point of view, the intravenous administration of gene therapy-based drugs
represents a promising approach to face diseases that affect the liver due to the natural tendency to
be accumulated in such an organ [23]. In addition, because there is not an absorption process, the
bioavailability of drugs is 100%. Considering that cancer disease represents around 65% of current gene
therapy clinical trials (http://www.abedia.com/wiley/) this route of administration is also interesting to
treat disseminated cancer cells that affect many organs. However, despite these relevant advantages,
its effect is highly hampered by the possible drug-induced hepatotoxicity [24] and by the relevant
biological extracellular barriers that the genetic material needs to overcome [25]. Consequently,
biomacromolecules such as ASOs, plasmids, siRNAs, or ribonucleoproteins (RNPs) are normally
administered with different kinds of gene delivery systems (viral or non-viral vectors) specifically
designed to make the process more efficient [26]. Usually, such biomacromolecules, in the “naked”
form (without any gene delivery system or chemical modification) can be easily degraded immediately
after administration by proteases and nucleases present in the blood. In addition, biomacromolecules
can also be phagocytosed by macrophages, and the bacterial origin of their components can induce
both cellular and humoral immune responses, which not only jeopardize their final performance but
can also have deleterious effects on the safety profile after their administration [27]. In circulation,
innate immune responses can occur through the activation of different kind of toll-like receptors
(TLRs) by impurities such as endotoxins or by bacterial components such as CpG motifs present on
the genetic material. Furthermore, an adaptive immune response can also be activated in the case
of pre-existing immunity [28]. In the case of genetic material delivered by non-viral vectors, some
physicochemical parameters such as zeta potential, particle size destruction, polydispersity index,
or hydrophobicity/hydrophilicity balance can also contribute to the compatibility with the immune
system [29]. Another relevant issue that needs to be considered is the natural tendency to accumulate
in the liver after intravenous administration, and the fact that such biomacromolecules, due to their
small size, below 5.5 nm, can be cleared quickly from systemic circulation through kidneys by renal
excretion [30]. In any case, although genetic material remains stable in bloodstream without eliciting an
immune response, the time required to reach therapeutic concentrations—the transfection process—can
be even more challenging if isolated and immune-privileged organs such as brain and eye are the final
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target of the gene therapy treatment. In this case, additional extracellular barriers that protect the brain
and eye from the rest of the organism such as the blood–brain barrier (BBB) and the blood–retinal
barrier (BRB) need to be overcome [31,32]. Due to the critical obstacles that extracellular barriers
represent, the design of effective and safe gene delivery systems for in vivo gene therapy represents a
really stimulating task for the scientific community. A schematic representation of extracellular barriers
is shown in Figure 1.
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quickly and properly through the cytosol to reach the RNA-induced silencing complex (RISC) in the 
case of siRNA, or the target mRNA in the case of ASOs that inactivate mature RNA. In the case of 
Figure 1. A brief schematic representation of both extracellular and intracellular barriers that
genetic material needs to overcome during the transfection process. ASO, antisense oligonucleotide;
siRNA, small interfering RNA; RNP, ribonucleoprotein; CME, clathrin-mediated endocytosis; CvME,
caveolae-mediated endocytosis; RISC, RNA-induced silencing complex; mRNA, messenger RNA; NPC,
nuclear pore complex.
2.2. Intracellular Barriers
Once xtracellular bar iers have bee , i r olecules still n ed to reach sufficient
amounts at cytoplasmic, or even nuclear le els, referably only on the target cells, in order to be
biologically active. Again, this intracellular trafficking is another arduous journey full of hurdles to beat
for the genetic material [33]. First of all, negatively charged ASOs, plasmids, siRNAs, and RNPs are
electrostatically repealed by the hydrophilic anionic proteins of the cell membrane, which jeopardizes
their cellular uptake and posterior internalization process [34]. In the absence of antibodies or
cell-specific ligands that promote a targeting effect, biomacromolecules can be internalized by different
pathways, of which clathrin-mediated endocytosis (CME), macropinocytosis and caveolae-mediated
endocytosis (CvME) are the most representative ones, forming the corresponding intracellular vesicles
referred as endosomes, macropinosomes, and caveosomes, respectively [35]. Although there is not a
unique consensus, and results in this research area are quite controversial, it is estimated that those
endocytosis pathways are connected, in a great (CME) or less extension (CvME and macropinocytosis),
Pharmaceutics 2020, 12, 198 6 of 29
to the lysosomes, where the acidic pH value degrades the genetic material. Consequently, the
transfection process is strongly affected [36]. If biomacromolecules escape on time from the acidic
environment of lysosomes, they still need to move quickly and properly through the cytosol to
reach the RNA-induced silencing complex (RISC) in the case of siRNA, or the target mRNA in the
case of ASOs that inactivate mature RNA. In the case of plasmids, RNPs, and some ASOs that act
on pre-RNA, the impermeability of the nuclear membrane represents another hurdle to overcome,
especially in quiescent and non-dividing cells [37,38]. Nuclear pore complexes (NPC) present on the
nuclear membrane of cells with a small 9 nm channel diameter that prevents the entry into the nucleus
of chemical compounds with a molecular weight over 45 kDa [38]. Other alternative to cross the
nuclear membrane is through active mechanisms mediated mainly by importins of the cytoplasm that
promote nuclear translocation [39]. Once inside the nucleus, or even before during the cytoplasmic
trafficking, biomacromolecules need to be dissociated from gene delivery systems to get access into
the transcriptional machinery of the target cell and produce the final biological effect [40]. A brief
schematic representation of intracellular hurdles is shown in Figure 1.
3. Non-Viral Gene Delivery Systems
Classically, gene delivery systems designed to overcome biological barriers are classified as viral
and non-viral vectors. Viruses, independently of their origin, have evolved over millions of years to gain
access into host eukaryotic cells in order to shuttle their genetic cargo. Nowadays, recombinant viruses
have been modified in the laboratory to reduce their pathogenic effect and to deliver the transgene
of interest into target cells [41]. During the last few years, relevant improvements have been made
mainly regarding their production methodology, safety profile, and genetic material packing capacity.
However, their biological origin hampers the commercialization process by regulatory authorities,
which clearly impacts on their final price [2,42]. In contrast, the non-viral vectors counterparts are
classically recognized for their safety profile, higher packing capacity, and low cost of production [43].
In any case, non-viral vectors for plasmid-based gene therapy have not yet reached clinical practice,
although research on this topic has quickly increased during the last few years, which has been
especially motivated by the impact that CRISPR/Cas technology has had on scientific community and
the need to deliver such genetic material in a safe and efficient way to target cells. In this sense, at a
preclinical level, non-viral vectors for CRISPR/Cas delivery predominate over the use of viral vectors
(70% versus 30%, respectively) [44]. Among non-viral gene delivery systems, we can differentiate the
development of physical and chemical methods.
3.1. Physical Methods
Basically, physical methods are vector-free systems based on a controlled and reversible
deformation of cytoplasmic membrane during short periods of time that allow the entry of genetic
material on target cells [22]. Although highly effective, these methods are normally restricted to ex
vivo gene therapy, which is mainly due to the challenge that represents the fine control of physical
parameters that produce the formation of transient pores into the cellular membrane in vivo conditions.
Such technological limitations can result not only in a loss of action but also in an increase of the
cellular toxicity [45]. Transient pores on cellular and even nuclear membranes can be induced by the
application of external electrical pulses, whose amplitude and duration are controlled, and depend
on the particular characteristics of the target cell [22]. Pores can also be created if a cell´s membrane
is mechanically deformed when cells are forced to pass through microfluidic-based channels which
the diameter is smaller than that of the cell [46]. Other physical methods that also can be used to
deliver genetic material into target cells efficiently include the direct microinjection of genetic material
into cells by a micropipette, the induction of cellular uptake by stimulation of the macropinocytosis
pathway with a hyperosmolar buffer containing sodium chloride and propanbetaine, or the hydynamic
injection. This last technique consists of the quick injection of genetic material into the tail of rodents in
volumes close to 10% of the total body weight [47].
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3.2. Chemical Methods
Although inorganic compounds such as magnetite, silica, or calcium phosphate, to name just a
few ones, have shown great potential to shuttle genetic material, most chemical vectors are based on
organic compounds such as cationic lipids or cationic polymers [48]. Amphiphilic cationic lipids for
gene delivery applications normally share four domains in their chemical structure [49]: a hydrophilic
polar head group, a hydrophobic apolar group, a linker, and a backbone. The positively charged
hydrophilic polar head group interacts electrostatically with the negatively charged genetic material,
obtaining the corresponding lipoplexes [50]. The composition of the hydrophobic apolar group can
affect the relevant physicochemical and biological parameters that influence the transfection process
such as the stability of the formulation, the DNA protection from nucleases, or the endosomal escape.
The chemical composition of the linker domain influences both the flexibility and degradation of
cationic lipids. Finally, the backbone group is the domain that separates the hydrophilic polar group
from the hydrophobic apolar group, of which asymmetric glycerol-based backbone domains are
the most commonly used for gene delivery purposes. A schematic representation of the general
chemical structure of cationic lipids for gene therapy applications can be observed in Figure 2. Small
changes in the chemical structure of any of the four domains can affect both the physicochemical and
biological parameters that regulate the transfection process [51]. Normally, to enhance the transfection
efficiency of cationic lipids, they are incorporated into vesicles made up of phospholipids resulting in
corresponding liposomes [52], or solid lipid nanoparticles (SLNs) if the core of the nanoparticle is a
solid lipid stabilized with surfactants [53]. Lipid nanoparticles have been used in the formulation of
Patisiran® to deliver siRNA genetic material in the liver after intravenous administration to suppress
the production of transthyretin in hereditary transthyretin-mediated amyloidosis (hATTR) patients [54].
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by a combination of both polycationic and polyanionic polymers, and with different organic d
inorganic materials such as polymers, agnetite, or lipids can be used also to deliver genetic material
for different purposes [58–62].
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for g ne delivery applications due to their high surface area-to-v lu e ratio, bio ompa ibility,
scalability, and precise particle distributi [63]. Additionally, NDs can be easily functionalized to
obtain hybrid compounds by electrostatic interac ions with hydrophilic cationic polymer such
, , , .
cationic groups, i.e., silane-NH2 or p lyamidoamine (PAMAM) [68], on the chemical structure
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of NDs by the formation of covalent bonds. Apart from NDs, graphene oxide (GO), a precursor of
graphene, is another material that has been recently investigated for gene delivery applications. GO is
a biocompatible material that is easy to synthetize, reproducible, and cheap. In addition, GO has high
dispersibility in water, and it can be easily functionalized with different kinds of polymers such as
polyethylene glycol (PEG) [69], polyethylenimine (PEI) [70], or chitosan [71].
4. Niosome Nanoparticles for Gene Delivery
Niosomes are non-ionic-based surfactant unilamellar or multilamellar vesicles with a bilayer
structure that have been used for around 40 years as drug delivery systems for different applications
with low toxicity and desired targeting properties [72]. As in the case of liposomes, hydrophilic heads
are orientated toward an aqueous solution, whereas hydrophobic groups are orientate toward an
organic solution, so both hydrophobic and hydrophilic drugs can be delivered by niosomes [73]. The
main difference between both nanocarriers is that in the case of niosomes, the phospholipids of liposome
vesicles have been substituted by non-ionic surfactants [74]. Compared to liposome counterparts,
niosomes are recognized for their higher chemical and storage stability, due to the presence of non-ionic
surfactants in their structure [75]. In addition, niosomes can be easily prepared at a low cost, and they
are less toxic than liposomes due to the presence of non-ionic surfactants [76,77]. All these characteristics
justify the research on niosomes as an interesting platform for gene delivery applications.
4.1. Components on Niosome Formulations
In addition to the non-ionic surfactant, which enhances the stability and is the main component of
niosomes, other chemical compounds can be incorporated into the niosome vesicles such as cationic
lipids that interact electrostatically with the negatively charged genetic material to obtain corresponding
nioplexes at different cationic lipid/genetic material ratios and “helper” components that improve
their biological performance [78]. Any slight modification of both the relationship and the chemical
structure of these components can affect, in a significant way, the relevant physicochemical parameters
of the formulation that regulate the transfection process such as the size, polydispersity index, and
morphology [79].
Non-ionic surfactants can be classified into four different categories: alkyl ethers, alkyl esters,
alkyl amides, and esters of fatty acids [73]. Some non-ionic surfactants that have been used in
niosomes designed for gene delivery applications include polyoxyethylene alkyl ether (Brij© [73]),
polysorbates (Tween© [80]), sorbitan fatty acid esters (Span© [81]), or poloxamers [82]. The most
relevant parameters of non-ionic surfactants to consider are the hydrophilic/lipophilic balance (HLB),
which can be used as a “saving guide” parameter to select the appropriate surfactant [83], the
critical packing parameter (CPP), which plays an important role in the vesicular-forming ability
of niosomes [84], or the gel liquid transition temperature (TC), which has a relevant impact on
the drug entrapped efficiency [85]. Among the cationic lipids, some of the most employed in the
elaboration of niosomes for gene delivery purposes include 2,3-di(tetradecyloxy)propan-1-amine
hydrochloride salt [86], 3β-[N-(dimethylaminoethane)-carbamoyl]-cholesterol hydrochloride salt
(DC-Chol, [87]), N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate salt
(DOTAP, [88]), 1,2-di-O-octadecenyl-3-trimethylammonium propane chloride salt [83], or
1-(2-dimethylaminoethyl)-3-[2,3-di (tetradecoxy) propyl] urea [51], to name just a few. Any slight
change of any of the four chemical domains of cationic lipids influences the transfection efficacy
mediated by niosomes [49]. Regarding “helper” lipids, they are normally neutral components i.e.,
cholesterol, that when used in appropriate amounts enhance both the rigidity and the colloidal stability
of formulations, promoting the gel liquid transition temperature of niosomes and the interactions with
the apolar group of non-ionic surfactants [89]. In addition, they can affect biological parameters such
as the cellular uptake and posterior intracellular trafficking of niosomes [90]. Squalene and squalane,
which are natural lipids belonging to the terpenoid family, as well as biochemical precursors of the
synthesis of cholesterol and other steroids, have also been incorporated in niosome formulations [90,91].
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Another commonly used “additional” component on niosome vesicles is PEG. When niosomes
“decorated” with hydrophilic PEG chains are administered into the bloodstream, the aqueous layer
on the vesicular surface avoids endocytosis by the reticuloendothelial system (RES), and it therefore
increases the half-live period of such niosomes in blood [92].
4.2. Niosome Preparation Methods
Niosomes can be easily elaborated by the solvent-evaporation method. Basically, both the cationic
and “helper” lipids are dissolved in a small volume of organic phase, where the aqueous phase
containing the non-ionic surfactant is added. After a brief sonication period, an emulsion is obtained.
Such emulsion can be left under magnetic agitation to evaporate the organic solvent, which will
produce the resuspension of the niosome vesicles into the aqueous phase [93]. A brief schematic
representation of the niosome components and their elaboration by the solvent evaporation process
can be observed in Figure 3.
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evaporation method, i whic the organic solvent is ev p rated in a ound-bottomed flask using
a rotatory vacuum evaporator. As a result, a dry film of lipids will be formed, which is thereafter
hydrated with the aqueous pha e above the trans tion temperature of the surfactant [94]. Anoth
inte esting and single-step alternative to elaborate niosomes wi hout the u e of organic solven s is
the bubble method. In this cas , l rge unilamell r niosomes vesicles can be obtained when both the
surfactant and lipids are heated over 70 ◦C in a buffer solution. Then, the dispersion is mixed with
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a high shear homogenizer followed by the bubbling of nitrogen gas at 70 ◦C [73]. In addition to the
bubble method, other alternative to obtain niosomes without the use of organic solvent is the lipid
injection method. In this case, lipids and surfactants are melted and thereafter injected into an aqueous
phase under heat and continuous agitation to get a final suspension of niosomes [95]. In order to obtain
small unilamellar niosome vesicles, the microfluidization method can be used. In this case, niosomes
are obtained when two fluidized streams pumped at specific speed interact with each other in small
and specifically designed microchannels for fast mixing [95]. Interestingly, this technique allows the
possibility of working in parallel with large volumes, which enhances the scalability of the production
process [96]. The precise and detailed elaboration of niosomes by other different techniques such as
trans-membrane pH gradient uptake, supercritical reverse phase evaporation, or the freeze and thaw
process can be looked up in two excellent articles that have been recently published [73,85].
Once niosomes have been prepared using any of the previously above-mentioned techniques,
the corresponding nioplexes can be obtained after the addition of a solution of the pertinent genetic
material to the colloidal suspension of niosomes (Figure 3). Due to the electrostatic interactions between
the positively charged amine groups of the cationic lipids incorporated into the niosome vesicles and
the negatively charged phosphate groups of the genetic material, nioplexes can be easily obtained at
different cationic lipid/genetic material ratios [76]. In the case the obtained niosomes are not going to be
used soon, they can be stored at 4 ◦C during several weeks, without affecting the main physicochemical
parameters that influence the gene delivery process [9].
4.3. Physicochemical Characterization of Niosome Nanoparticles
Normally, after niosome elaboration and before performing any biological experiments, some
of the most relevant physicochemical properties involved in the nucleic acid delivery of niosomes
are evaluated as a screening methodology to select the most suitable composition and concentration
of the chemical components [78]. Dynamic light scattering (DLS) can evaluate the hydrodynamic
diameter and the polydispersity index (PDI) of both niosomes and corresponding nioplexes in a
Zetasizer instrument, while the morphology and distribution of niosome colloidal dispersions can
be examined by different microscopic techniques [76]. The DLS technique is based on the random
Brownian movement of small particles and the light scattered when a laser irradiates the colloidal
suspension, which is highly dependent on the ion concentration [78]. The hydrodynamic diameter
is usually obtained by cumulative analysis, which requires a narrow and monodisperse sample
distribution, typically with PDI values below 0.5 for comparative purposes [97]. When genetic material
binds to the surface of cationic niosomes at different cationic lipid/genetic material ratios, normally,
the nioplexes size fluctuates slightly due to the condensation effect produced by the electrostatic
interaction, which would decrease the size and the space demanded by the genetic material, which
would increase in vesicular size [91]. Such slight alteration of the final size can affect the endocytosis
pathway and consequently the posterior intracellular trafficking of niosomes [34,90,98]. In addition to
size, the PDI value also changes upon the incorporation of genetic material on the surface of cationic
niosomes. In this case, polydispersion typically increases due to the heterogeneous distribution of
such genetic material [49]. Normally, niosomes exhibit spherical morphology that can be evaluated
under transmission electron microscopy (TEM) and cryo-TEM [76]. These techniques can require
the addition of staining agents, and they can also be used to evaluate the size and distribution of
niosomes, although they may not correlate with DLS due the difference regarding the manipulation of
the samples [91]. If the samples to analyze are in solid form, scanning electron microscopy (SEM) can
also provide information about the morphology of niosomes. For a more precise analysis, for instance,
to determine the characteristics of bilayers, scanning tunneling microscopy (STM) or small angle X-ray
scattering (SAXS) techniques can be used [99,100].
The degree of the buffering capacity of cationic niosomes represents the potential of such non-viral
vectors to escape from the degradation in the acidic compartment of lysosomes due to the incorporation
of H+ into the lipid structure. Such buffering capacity can be measured by an acid–base titration
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assay [101]. Briefly, colloidal suspensions of niosome formulations are titrated with a solution of NaOH
to reach a basic pH value. Next, niosomes are titrated again, but in this case with an HCl acid solution,
to evaluate the capacity to absorb H+ when different volumes of the acid solution are added.
Another relevant parameter that can be determined to predict the stability of niosomes is the zeta
potential (ζ). This value is related to the superficial charge of the formulation and can be obtained
from a Zetasizer instrument by a laser Doppler velocimetry (LDV) technique [86]. Typically, it is
accepted that ζ values of nanoparticles over 20 mV (either negative or positive) prevent aggregation by
electrostatic repulsion [102]. When nioplexes are elaborated, positively charged cationic groups of
niosomes are partially neutralized by the negatively charged phosphate groups of genetic material,
resulting in a decrease of superficial charge which will depend on the cationic lipid/genetic material
ratio [83]. Normally, nioplexes are elaborated at positive cationic lipid/genetic material ratios to enhance
the cellular uptake of such nioplexes by interaction with the negatively charged cell membranes.
Additionally, the interaction between the cationic lipids of niosomes and the genetic material can also
be evaluated at a molecular level by isothermal titration calorimetry through the measurement of
the heat released when such binding occurs [103]. Agarose gel electrophoresis assays can be used to
evaluate the capacity of niosomes to condense, release, and protect the genetic material from enzymatic
digestion [86]. In this sense, it is well established that a delicate balance between condensation and
release capacity needs to be obtained at an appropriate cationic lipid/genetic material ratio to guarantee
the condensation and protection efficiency, as well as the release of such genetic material to reach the
nucleus of the target cell [91].
The stability of non-viral vectors is another issue that needs to be considered, due to its relevant
effect not only on physicochemical parameters, but also on biological properties [85]. To evaluate
the stability, some of the previously commented parameters such as particle size, PDI, or ζ value
are monitored in different temperature and humidity conditions over time [104–106]. An interesting
approach to enhance the physical stability of niosomes is to obtain a stable dry powder formulation by
lyophilization that can later be resuspended in the appropriate solvent before use. In this case, the
selection and the concentration of the cryoprotector, along with the parameters of the lyophilization
process need to be evaluated to guarantee the stability of the dry powder [107,108]. The analysis
of some of the previously described physicochemical parameters on a niosome formulation can be
observed in Figure 4.
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4.4. In Vitro Biological Evaluation of Nioso es for ene elivery
Once the most relevant physicochemical parameters that affect the transfection process have been
analyzed, and before performing any in vivo assay, several in vitro studies are normally performed
to evaluate the toxicity and the efficiency of different formulations as a screening methodology of
different candidate formulations. The cationic lipids in the structure of the niosome vesicles can
destabilize the cell membrane, induce apoptosis, and therefore be toxic at high doses [109]. To
minimize these effects, different strategies can be followed such as to increase the incorporation of
the non-ionic surfactant, reduce the cationic lipid/genetic material ratio, or reduce the exposition time
of nioplexes [49]. Since cell toxicity is mainly caused by the chemical structure of the cationic lipid
and also has a clear cell-dependent effect, each application needs to be individually addressed [110].
Cell viability can be qualitatively evaluated by microscopy or can be quantified by flow cytometry
with the use of appropriate fluorescent dyes such as propidium iodide or 7-Amino-actinomycin
D (7-AAD), which penetrate into damaged cells [97]. Alternatively, colorimetric assays, such as
CCK-8 (Cell Counting Kit-8) or MTT (3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide;
succinate dehydrogenase activity), can be used to evaluate cell viability by absorbance [49]. Normally,
dead cells are excluded from the transfection efficiency results. A common strategy to evaluate the
initial transfection efficiency of niosomes is the use of reporter plasmids based on the luciferase of
fluorescence [111,112] (Figure 5). It is worth mentioning that to get an optimal therapeutic effect, both
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the percentage of cells that incorporate the transgene, along with the amount of protein expression by
transfected cells need to be considered. Although this approach can provide an overview of the gene
delivery efficiency of niosomes, further readjustments on cationic lipid/genetic material ratio need
to be performed when moving to therapeutic plasmids, since both the composition and size of the
plasmid directly influence the transfection efficiency process [113].
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The knowledge of the e docytosis pathway and th posterior intracellular trafficking t reach
the nucleus of t rget cells can be useful to design more effici a safer niosome vesicles for ge e
delivery applications [51]. For th t purpose, specific fluorescent endocy ic markers such as dextrans,
chole a toxin B, or transferrin can be used to stain the most rep entative endocytosis pathways
(macropinocitosis, caveolae, nd clathrin- diated ndocytosis, p c ively). The colocalization
of su h dyes with fluoresc nt labelled niosomes, or preferably, fluorescent plasmids attach on
the surface of niosomes can be qu litatively evaluated by nfocal microscopy [91], or quantified
by different overlay co fficients, such as Mander´s or Pearson´s colocalization coefficients [9,114]
(Figu e 5). Additionally, intracellula trafficking studies can be completed with lysosome markers such
as lysotrackers [90] or with different uptake inhibitors such as geni tein, wortmannin, or chlorpr mazine,
to inhibit selectively caveolae, macropinocytosis, or clathrin-mediated endocytosis, respectively [115].
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All of the previously mentioned in vitro studies can be performed as a proof of concept in Human
Embryonic Kidney (HEK-293) culture cells, which is a one of the most employed models for transfection
studies [116]. However, because transfection efficiency is a highly cell-dependent process, other cell
lines that are more representative such as ARPE-19 or NT2 cells can be used for retinal and brain
gene delivery purposes [91,93]. Additionally, and as a more realistic scenario that resembles in vivo
conditions, primarily the culture cells of both retina and brain can be used [51]. When primarily
culture cells are used, the transfection efficiency decreases considerably when compared to values
obtained in immortalized cells lines. Therefore, primarily cultures are normally used to evaluate the
kind of cells that have been transfected by immunohistochemistry rather that the transfection efficiency
in quantitative terms [9,51]. In the case of immune-privileged organs such as the brain and eye, in
addition to culture cells, different and sophisticated in vitro models based on microfluidic chips of
both the BBB and BRB can be used to better mimic the in vivo conditions and predict their behavior
performance [117,118].
5. Eye as Main Goal
The old concept of immune privilege appeared in 1948, when this term was applied to sites in the
body where foreign tissue grafts can survive for extended periods of time, whereas similar grafts placed
at a regular site in the body are acutely rejected [119]. This concept needs to be differentiated from the
privileged immunity concept, which refers to the capacity of specific organs to select the most suitable
and effective immune response to guarantee their proper functions in health and pathology [120]. In
this review, we will refer to eye as an immune-privileged central nervous system (CNS) organ, in the
sense that such organs are less likely to react against the inflammatory processes caused by foreign
agents, because they are protected from the rest of the organism by the BBB [121].
5.1. General Concepts
The eye has been classically considered as an amenable organ to be targeted by in situ gene
therapy [122]. Due to its reduced size and compartmentalized anatomy, small amounts of vector
are required to get a satisfactory effect, and such vectors can be placed in close proximity to the
target cells, rather than being systemically administered, which minimizes the potential adverse
reactions [123]. Furthermore, due to the isolation from the rest of the organism, the risk of adverse
effects is considerably reduced [124]. In addition, the visual function and retinal structure can be
evaluated through non-invasive methods [125], and because most of the inherited retinal diseases are
symmetric, the untreated eye can be used as control, reducing the number of experimental animals in
the laboratory at a preclinical level [126].
The recently approved by FDA (Food and Drug Administration) and EMA (European Medicines
Agency) Luxturna® drug represents the most successful example of retinal gene therapy. Luxturna®
is indicated for the treatment of Leber congenital amaurosis type 2 (LCA2) disease due to bi-allelic
mutations in the RPE65 gene expressed in RPE cells. With this gene therapy strategy, a functional copy
of the required gene is delivered into the subretinal space by adenoasociated virus (AAV) vectors [127].
Although the results obtained by Luxturna® offer an encouraging future for gene therapy applied
in ophthalmology, the translation of such success to other retinal conditions will not be an easy task.
AAV vectors target mainly the RPE layer, where the RPE65 gene codifies the required enzyme of the
visual cycle. However, most of the genetic mutations of the retina affect the cells of the neuroretina,
especially photoreceptors (PR), where AVV are not so efficient [128]. In addition, it has been reported
that AAV virus can enter into the visual pathways of brain after subretinal injection, which rises major
concerns due to the potential to trigger unexpected outcome effects [129]. In addition, AVV packing
capacity is limited to approximately 4.7 kb, which jeopardizes its use to deliver genes with larger coding
sequences i.e., ABCA4, MYO7A, or CEP290 for the treatment of relevant pathologies of the retina such
as Stargardt disease, Usher syndrome type 1B, or LCA type 10, respectively [122]. Another relevant
concern is the high cost of AVV–based Luxturna® treatment, which is around $850.000 per-patient in
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the U.S., which makes it difficult for affected patients to access to such innovate treatments. Therefore,
it looks logical to explore other safer and cheaper alternatives to deliver genetic material into the retina.
In this sense, non-viral vectors based on cationic niosomes have recently shown promising results at a
preclinical level.
5.2. Niosomes for Gene Delivery to the Retina
The first evidence of niosome vesicles as efficient gene delivery systems into the retina was
reported in 2014, when niosomes based on the 2,3-di(tetradecyloxy)propan-1-amine cationic lipid,
combined with the squalene “helper” lipid and polysorbate 80 non-ionic surfactant were able to deliver
in a safe and efficient way the reported EGFP (Enhanced Green Fluorescent Protein) plasmid to the
rat retina after both intravitreal and subretinal administrations [91]. Previously, it was reported that
the aforementioned cationic lipid was able to silence gene expression upon covalent conjugation
with RNA molecules [130], and that corresponding lipoplexes transfected efficiently RPE and some
PR cells after subretinal injection [50]. These data reflect the suitability of such cationic lipids to be
used for gene delivery purposes and its inclusion in a novel niosome formulation where non-ionic
surfactant polysorbate 80 was incorporated to enhance the stability of vesicles. In addition, squalene,
a natural lipid belonging to the terpenoid family, was also incorporated as a “helper” lipid due to
the promising transfection results obtained previously with this compound in other cationic lipid
emulsions [131,132]. Nioplexes around 200 nm and +25 mV were obtained upon addition of the
reported pCMS-EGFP plasmid at a 15/1 cationic lipid/DNA ratio. Such nioplexes entered mainly by
the clathrin-mediated endocytosis pathway in cultured RPE cells, and immunohistochemistry studies
reflected that nioplexes were able to deliver the reported plasmid into different layers of the retina,
depending on the administration route. Interestingly, protein expression was still observed 28 days
after both subretinal and intravitreal injections.
The following year, in 2015, a ternary non-viral vector based on protamine/DNA/niosome
expressed locally the EGFP protein in PR close to the in situ subretinal administration, and a more
uniform distribution of the protein expression was observed in the inner layers of the retina, especially
in ganglion cells, after intravitreal injection. As in the previous study, protein expression persisted for at
least one month after both administrations [86]. Protamine is an FDA-approved small peptide obtained
from the sperm of herring and salmon that efficiently condenses DNA due to its positive charge.
Arginine sequences on protamine promote the nuclear import of genetic material, which is especially
relevant in slow-dividing retinal cells [133]. However, the high hydrosolubility of protamine hinders the
interaction with lipophilic membrane cells [134]. Consequently, to enhance such interaction, protamine
was incorporated in lipid formulations such as SLNs [135] or liposomes [136] but not in niosomes for
retinal gene delivery. The incorporation of protamine in ternary vectors (protamine/DNA/niosomes,
at 1:1:5 ratios, respectively) reduced the size to 150 nm and enhanced DNA condensation capacity.
Interestingly, it also reduced the amount of cationic lipid required to transfect the rat retina, and
therefore, increased cell viability.
Since small modifications on the chemical structure of the components in the cationic niosomes
can affect the gene delivery capacity, in 2016, the transfection efficiency of three different cationic lipids
was evaluated in rat retina [51]. Such cationic lipids shared the same hydrophobic tail and the same
glycerol-based building block, differing only among them on the polar head formed by an amino
group, a glycine triglycine, and a dimethylaminoethyl group. Both squalene and polysorbate 80 were
used as “helper” lipids and non-ionic surfactants, respectively. After an extensive physicochemical
characterization and in vitro evaluation in different cell lines, the results showed that nioplexes based
on the cationic lipid that had the dimethylaminoethyl structure on the polar head group were the
most efficient for retinal gene delivery. After the intravitreal injection of nioplexes at a 30/1 cationic
lipid/DNA ratio, EGFP expression was uniformly distributed, overall, in the ganglion cell layer. The
PEG chains on the polysorbate 80 non-ionic surfactant could prevent the aggregations of cationic
niosomes with negatively charged components, glycosamineglycanes, and fibrilar structures present
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in the vitreous, enhancing therefore the diffusion through the vitreous humor and the transfection
efficiency [137]. Interestingly, after intravitreal injection, protein expression was also detected in some
outer cells of the retina. The transfection of PR and RPE cells by intravitreal injection instead of
subretinal injection represent a great challenge to face genetic pathologies that affect the outer segments
of the retina, avoiding the harm of sensitive neuronal tissue that is classically associated to subretinal
injection [138].
As in the case of squalene, lycopene is another natural terpenoid compound found at high
concentration levels in the eye, which is classically known by its biological properties as an
antioxidant agent, cytoprotector, and immunomodulator, among many others [139]. Therefore,
in 2017, lycopene-based niosome formulations were elaborated by the solvent evaporation
technique and evaluated for retinal gene delivery capacity prior to physicochemical and biological
characterization [140]. The resulting nioplexes at an 18/1 mass ratio showed nanometric size with
low polydispersion, spherical shape, positive superficial charge, and the capacity to stabilize DNA
against enzymatic degradation. The cellular uptake of such nioplexes was mediated mainly by the
macropynocitosis and caveolae pathways. After intravitreal injection, the outer segments of the retina
were also efficiently transfected in a safe way.
As the main component of a niosome vesicle is the non-ionic surfactant, it looks logical to study
the influence of different non-ionic surfactants in the design of niosomes for retinal gene delivery
applications. In fact, in 2018, three niosome formulations that only differed in the polysorbate non-ionic
tensioactive were elaborated by the solvent evaporation technique. The three niosome vesicles shared
the same commercially available cationic lipid 1,2-di-O-octadecenyl-3-trimethylammonium propane
(DOTMA), the same “helper” lipid squalene, and had polysorbate 20, polysorbate 80 or polysorbate 85 as
non-ionic tensioactives [83]. Polysorbate 20 has the highest HLB value (16.7) and upon the incorporation
of reported pCMSEGFP plasmid on the surface of corresponding niosomes to obtain nioplexes at a 2/1
ratio of cationic lipid/DNA, RPE cultured cells were successfully transfected without signs of toxicity.
Intracellular trafficking studies showed that the hydrophilic nature of the polysorbate 20 non-ionic
surfactant promoted caveolae-mediated endocytosis and evaded colocalization with the lysosome
compartment, which to some extent could explain the difference observed in transfection efficiency
among the three niosome formulations. In the primary culture cells of retina, such formulations were
well tolerated, in contrast to the commercially available Lipofectamine 2000TM, and they expressed
the fluorescent protein mainly in glial cells. After in situ subretinal injection, protein expression was
observed mostly in RPE cells and also in the inner layers of the retina, whereas intravitreal injection
transfected overall the ganglion cell layer.
However, the success of gene therapy does not only rely on the composition of the gene delivery
system. In fact, vectors are only one part of the complex formulation. The other half is conditioned by
the characteristics of the genetic material. In this sense, in 2019, the same cationic niosome formulation
and three different GFP-encoding genetic materials consisting of minicircle (2.3 kb), its parental plasmid
(3.5 kb), and a larger plasmid (5.5 kb) were combined to form nioplexes. Obtained results showed that
the lack of unmethylated CpG regions in the mcDNA rendered nioplexes with better physicochemical
properties, stability, cell tolerance, and transfection efficiency in different layers of the rat retina after
both intravitreal and subretinal injections, which reinforce the importance of the genetic material size
and composition in the design of gene therapy vectors.
Taking into account that cationic niosomes represent a tunable platform for retinal gene
delivery applications, in 2019, chloroquine was incorporated as a “helper” component into cationic
niosomes based on the 2,3-di(tetradecyloxy)propan-1-amine (hydrochloride salt) cationic lipid, and a
mixture of both poloxamer 188 and polysorbate 80 as non-ionic surfactants [115]. Chloroquine is a
4-aminoquinoline drug with promising properties for retinal gene therapy, since it can cross the BRB,
interacts with negatively charged DNA molecules, and also promotes endosomal scape [141]. However,
its clinical application is limited due to the high toxicity exhibited [142]. Therefore, chloroquine was
incorporated within a niosome formulation to keep its gene delivery properties at low doses, reducing
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its toxic effect. At a 10/1 cationic lipid/DNA ratio, the resulting chloroquine concentration was only
25 µg, and it did not induce any significant cytotoxicity. In contrast, protein expression through
different layers of the retina was increased as can be observed in Figure 6.
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Figure 6. In vivo applications of niosomes in retina. Niosomes transfected different layers in the
rat retina, depending on the administration route. Retinal cross sections micrographs obtained by
confocal microscopy (A1,B1), confocal fluorescence micrographs of whole mount (A2,B2). Adapted
with permission from Mashal et al. [114]. Copyright 2019, Elsevier B.V.
6. Brain as Main Goal
As in the case of vision, brain functions are essential for survival. Therefore, sophisticated
mechanisms have been developed over many years of evolution to protect and isolate such sensitive
organs with limited regeneration capacity from potentially damaging effects [31]. In the case of the
brain, the tightly joined endothelial cells of BBB are impermeable for almost 100% of macromolecular
and over 98% of small molecular drugs [143]. The transport of essential nutrients such as amino acids
and glucose is mediated by specific receptors present in the BBB [31]. Although recent advances on
gene therapy offer reasonable hope to face some devastating pathologies that affect relevant CNS
organs such as the brain and eye, the isolation of those organs from the rest of the organism by the
BBB and BEB prevents delivery systems from crossing such hurdles [43,144]. Consequently, effective
gene therapy approaches to treat both inherited and acquired diseases of brain rely on the in situ
administration of genetic material by invasive routes [43]. Such cumbersome gene delivery strategy
can jeopardize the acceptance of treatments and increase aftercare cost due to the treatment of related
side effects [145].
6.1. General Concepts
Gene therapy has shown great progress in clinical trials over the last decade to face both inherited
and acquired devastating brain diseases that do not have a reasonably effective treatment with
conventional drugs (https://alliancerm.org/publication/q2-2019-data-report). In the case of inborn
metabolism mutations of one gene that affect the brain, such as mucopolysaccharidoses or Canavan
disease, the approach normally consists of the delivery of a functional copy of the gene to restore the
normal phenothype [146–148]. However, in the case of brain-acquired diseases, where more than one
gene can be affected, such as brain cancer, Alzheimer’s, or Parkinson’s diseases, the genetic approach is
more challenging, since the molecular basis of those disorders are still not understood [148–150]. BBB
hampers the entry of gene expression vectors into the brain; consequently, gene treatments must be
given after an invasive craniotomy, which in many cases jeopardizes the acceptance of patients enrolled
in clinical trials due to the cumbersome approach and related side effects that increase the after-care
cost as a consequence of additional hospital visits [151]. Moreover, because of the low diffusion of
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genetic material after in situ brain administration by craniotomy, few cells can be targeted by vectors,
which prevent the access of the genetic material to the rest of the brain cells [152].
Apart from the route of administration, another confounding factor in brain gene therapy is the
challenge that represents the delivery of genetic material into neurons. Brain neurons show strict
organization to form complex neuronal networks, limited regenerative capacity, and low division rate,
which hampers the entry of exogenous DNA into the nucleus [153]. Additionally, the molecular bases
of many neurological disorders that affect the brain are still not understood.
Previously commented limiting factors, along with the need to use appropriate vehicles that are
able to deliver efficiently the genetic material, justify the hard path of brain gene therapy to reach
clinical practice. In fact, although many phase I clinical trials have been reported; only a few have
reached phase II [154]. However, with the new emerging technologies applied to gene therapy, the cure
of brain diseases might look like a reasonable option in the near future [155]. One of the most promising
approaches is to explore the use of non-viral vectors as gene delivery systems due to their safer profile,
easy production capacity, and lower cost when compared to their viral vector counterparts [154].
6.2. Niosomes for Gene Delivery to the Brain
Among non-viral vectors, niosomes based on cationic lipid 1-(2-dimethylaminoethyl)-3-[2,3-di
(tetradecoxy) propyl] urea, combined with squalene as a “helper” lipid and polysorbate 80 non-ionic
surfactant, were recently able to transfect the rat cerebral cortex after in situ administration [51]. Such
cationic niosomes were elaborated by the solvent evaporation technique and exhibited a diameter
of 200 nm with a low PDI value (0.21) and positive superficial charge over 30 mV. Physicochemical
parameters were maintained after 100 days when formulations were stored at 4 ◦C. Upon the addition
of reporter pCMSEGFP plasmid in their surface by electrostatic interactions at a 30/1 cationic lipid/DNA
ratio, the resulting nioplexes were able to transfect efficiently both neurons and non-neuron cells
in primary cultures obtained from the cortex of rat embryos, as revealed by immunohistochemistry
studies as can be observed in Figure 7.
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Figure 7. In vivo applications of niosomes in brain. (A) White arrows in the right side indicated
identified neurons (red) that express EGFP (green). (B) Non-neuron cells (NeuN−) with glia morphology
that express EGFP (green) were indicated by yellow arrows. Adapted with permission from Ojeda
et al. [51]. Copyright 2017, Elsevier B.V.
In 2018, another niosome formulation elaborated with a commercially available DOTMA cationic
lipid, lycopene as a “helper” lipid and polysorbate 60 as a non-ionic surfactant, exhibited high levels
of protein expression in both primary cortical cultures of rat embryos and in in vivo conditions after
intracranial injection in the cortex [114]. Such niosomes were characterized in terms of size, superficial
charge, polydispersity, or capacity to protect genetic material against enzymatic digestion in an agarose
gel electrophoresis assay. After physicochemical characterization, in vitro studies were performed in
human neuronal precursors NT2 cells. NT2 cells are considered as an attractive model to evaluate
CNS gene delivery efficiency, which is mainly due to their potential capacity to be easily differentiated
into both glial and neuronal cells, upon exposition to retinoic acid [93,156]. Additionally, genetically
modified NT2 cells can be transplanted into CNS and migrate to specific regions of brain, acting as an
interesting cell-based gene delivery platform to repair brain damages [157]. After 24 h post-transfection,
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nioplexes formulated at a 14/1 cationic lipid/DNA ratio exhibited approximately half the transfection
capacity of the commercially available Lipofectamine® 2000 but higher cell viability. Intracellular
trafficking studies performed with both specific dye markers and blockers of most representative
endocytosis pathways revealed higher cellular internalization by both caveolae and clathrin-mediated
endocytosis than by macropinocytosis. In addition, buffering capacity studies revealed endosomal
properties that could explain, at least in part, the high transfection efficiency observed in NT2 cells.
Next, and before brain administration into the rat cerebral cortex, the primary cortical cultures of rat
embryos were exposed to nioplexes in order to better mimic the in vivo conditions. In this scenario,
NeuN- cells with gial morphology expressed the protein, which was probably due to their phagocytic
and mitotic activity [158]. The lack of protein expression into neurons was confirmed after the in situ
intracranial injection of nioplexes. Again, only NeuN- cells (neuroglia and cells in blood vessel wall)
expressed the protein. In any case, although this niosome formulation failed to transfect brain neurons
after intracranial injection, high levels of protein expression in glial cells suggest its possible application
into CNS in glia-related neurological disorders such as epilepsy, Alzheimer’s, or Parkinson’s diseases,
to name some of the most representatives ones [159].
Considering the previously reported properties of poloxamer 188 regarding biocompatibility and
capacity to protect neurons against brain injury [160], its incorporation into niosomes based on the
hydrochloride salt of 2,3-di(tetradecyloxy)propan-1-amine cationic lipid and polysorbate 80 surfactant
was evaluated [82]. Therefore, two niosome formulations that differed only regarding the presence or
absence of the non-ionic surfactant poloxamer 188 were elaborated by the reverse-phase evaporation
technique and characterized to deliver the genetic material into the rat brain cortex. When poloxamer
188 was incorporated into the niosomes, the sizes of niosomes increased, which was probably due to
the high HLB value of poloxamer 188 and to the interaction with the cationic lipid [161]. However, no
significant change in zeta potential was reported, being over +40 mV. Agarose gel electrophoresis assays
revealed that out of all the cationic lipid/DNA ratios studied, nioplexes based on niosome formulated
with both non-ionic surfactants polysorbate 80 and poloxamer 188 at equal mass ratios protected the
genetic material from enzymatic degradation. However, in the case of niosomes formulated only
with polysorbate 80 as a non-ionic surfactant, at low cationic lipid/DNA ratios, the genetic material
was degraded, which was probably due to the negative zeta potential value of those nioplexes that
were able to condense but not protect the DNA. In vitro experiments on NT2 cells revealed that the
addition of poloxamer 188 to niosomes enhanced the cell viability and the cellular uptake mediated
by caveolae and macropinocytosis, which could explain the higher transfection values observed. In
primary cortical cultures of rat embryos, gene expression was mainly observed in neurons with no
signs of toxicity. However, when moving to in situ intracranial administration, nioplexes transfected
glial cells but not the neurons of the cortex. Such in vitro and in vivo discrepancy could be explained
by the different gene delivery mechanism in both biological scenarios.
Interestingly, the following year, in 2019, the same niosome formulation based on the
2,3-di(tetradecyloxy)propan-1-amine cationic lipid and a mixture at equal weight ratios of both
polysorbate 80 and poloxamer 188 non-ionic surfactant was able to deliver the pUNO1-hBMP7 plasmid
into NT2 (NTera2/D1 teratocarcinoma-derived) cells [162]. The human bone morphogenetic protein
7 (hBMP7) belongs to the transforming growth factor β superfamily, and its role is relevant for the
development of bone, kidney, and nervous tissues [163]. At a 6/1 cationic lipid/DNA ratio, a significant
release of hBMP7 (5.7 ng/mL) was detected in the supernatants of transfected cells, with no signs of
toxicity. Next, the tumor-suppressive effect of hBMP7-expressing NT2 cells was investigated on the
glioma cell line C6 in a transwell indirect co-culture system to avoid the drawbacks of direct co-culture
system. In vitro co-culture results showed that the BMP7-overexpressing NT2 cells hampered the
migration of C6 glioma cells, which highlights the potential of NT2 cell-based delivery of hBMP7 for
impeding the metastasis of glioma cells [162].
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7. Future Perspectives
After more than three decades of hard work, with normal ups and downs, nowadays, gene
therapy represents a real and revolutionary clinical option, not only to treat but also to cure the
molecular basis of some serious disease. In any case, and despite the promising future that awaits gene
therapy, some controversial issues still need to be improved. At the moment, all of the gene therapy
treatments approved for human use by different regulatory authorities are based on viral vectors, which
rises controversy regarding their safety profile, limited gene-packing capacity, large-scale production,
and high costs [164]. Consequently, during the last years, research on non-viral vectors has gained
“momentum” as a safer alternative to their viral vectors counterparts, and the number of clinical trials
has considerably increased since 2010 (www.clinicaltrials.gov).
In the case of eye and brain, which according to the old immune-privileged concept are organs
isolated and protected from the systemic immune response of the organism [119], the use of less
immunogenic non-viral vectors [165] is even more relevant to avoid damage in such sensitive
organs [43]. In addition, in order to develop a more friendly approach, at a preclinical level, many
nanotechnology-based formulations of different materials, shapes, and compositions can be tailored
with specific ligands to overcome both BRB and BBB and deliver their cargo by non-invasive routes of
administration such as topical instillation on ocular [166–169] and nose surfaces [170,171] (Figure 8).
Considering the versatility of the cationic niosome platform for gene delivery applications, some of the
biomaterials commonly used to overcome the BRB and BBB, such as transferrin, Annexin V, insulin, or
gemini surfactants, could be incorporated in novel niosome vesicles, bearing in mind the recent results
reported after the in situ administration of such non-viral vectors in both retina and brain cortex tissues.
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Although it is possible to reach the brain cortex and retina in small animals at a preclinical level
by non-invasive routes of administration, in order to reach the regular clinical practice, enough gene
expression should be reached selectively in the specific target cells of those tissues in larger species,
avoiding the distribution of the delivered gene in other tissues. At present, non-invasive approaches to
reach both the brain cortex and retina require multiple administration doses at high concentrations,
which enhance systemic absorption, and therefore, the appearance of unwanted effects in other tissues.
In this sense, the use of cell-type specific promoters, inducible promoters, or the rapamycin regulation
system offer a reasonable option to confine gene expression only in specific cell types, which avoids
off-target effects in other cells [153]. Hence, the future direction to design non-viral vectors based
on novel cationic niosomes to face inherited and acquired diseases of eye and brain by non-invasive
routes of administration requires not only the use of appropriate biomaterials and targeting ligands
coupled to the niosome platform but also the selection of the appropriate genetic material with its
intrinsic characteristics. In any case, it is clear that such ambitious goals need to be addressed by a
multidisciplinary approach. In this sense, the design of novel smart imaging and sensing catheter
devices for surgical interventions based on next-generation technologies at the point of intervention
would also minimize both the damage and cost occasioned by the in situ administration of gene
therapy-based drugs in the brain and retina.
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